Combination therapy in metastatic renal cell cancer

Seminars in Oncology

Volumn 40, Issue 4, 2013, Pages 472-481

  Ravaud, Alain ^a,b,c   Gross Goupil, Marine ^a   Bellmunt, Joaquim ^d  

^a HÔPITAL SAINT ANDRÉ   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c Centre of Clinical Investigation Clinical Epidemiology   (France)

^d HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHOXY 2 METHYL 3 (3,4,5 TRIMETHOXYBENZOYL)BENZOFURAN 7 YL PHOSPHATE DISODIUM; ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; BUPARLISIB; CAPECITABINE; DALANTERCEPT; ERLOTINIB; EVEROLIMUS; GEFITINIB; GEMCITABINE; PAZOPANIB; PERTUZUMAB; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; TRASTUZUMAB; TREBANANIB;

ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APPETITE; ARTICLE; ASTHENIA; BLEEDING; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PROGNOSIS; CONSTIPATION; COUGHING; CYTOPENIA; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EPISTAXIS; FATIGUE; FEVER; HAND FOOT SYNDROME; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; KIDNEY METASTASIS; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SIDE EFFECT; STOMATITIS; SYNDROME; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; VOMITING;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84883179205     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.05.010     Document Type: Article

References (54)

1. B. Escudier, T. Eisen, and C. Porta Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 23 Suppl 7 2012 65 71
2. NCCN guidelines NCCN Website [nccn.org]. 2012.
3. Molina AM, Motzer RJ, Heng DY. Systemic treatment options for untreated patients with metastatic clear cell renal cancer. Semin Oncol. 2013;40:435-42.
4. Escudier B, Gore M. Sequencing therapy in metastatic renal cell cancer. Semin Oncol. 2013;40:464-70.
5. S. Kummar, H.X. Chen, and J. Wright Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements Nature Res Drug Discov 9 2010 843 856
6. G.E. Konecny, M.D. Pegram, and N. Venkatesan Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells Cancer Res 66 2006 1630 1639
7. J. Baselga, J. Cortes, and K. Sung-Bae Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer N Engl J Med 366 2012 109 119
8. K.T. Flaherty, J.R. Infante, and A. Daud Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations N Engl J Med 367 2012 1694 1703
9. I. Sánchez-Hernández, P. Baquero, L. Calleros, and A. Chiloeches Dual inhibition of (V600E) BRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism Cancer Lett 28 2012 244 255
10. M. Atefi, E. von Euw, and N. Attar Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway PLoS One 6 2011 e28973
11. M.W. Karaman, S. Herrgard, and D.K. Treiber A quantitative analysis of kinase inhibitor selectivity Nat Biotechnol 26 2008 127 132
12. D.R. Feldman, M.S. Baum, and M.S. Ginsberg Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma J Clin Oncol 20 2009 1432 1439
13. B.I. Rini, J.A. Garcia, and M.M. Cooney A phase I study of sunitinib plus bevacizumab in advanced solid tumors Clin Cancer Res 15 2009 6277 6283
14. J. Medioni, E. Banu, and D. Helley Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series Eur Urol 56 2009 207 211
15. J.A. Sosman, K.T. Flaherty, and M.B. Atkins Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC) J Clin Oncol (Meeting Abstracts) 26 2008 5011
16. N.S. Azad, E.M. Posadas, and V.E. Kwitkowski Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity J Clin Oncol 26 2008 3709 3714
17. Flaherty K, Manola J, Pins M, et al. Results of the BeST Trial. Paper presented at the 11th International Kidney Cancer Symposium; October 2012; Chicago, IL.
18. J.M. Lee, G.A. Sarosy, and C.M. Annunziata Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity Br J Cancer 102 2010 495 499
19. S. Sharma, V. Abhyankar, and R.E. Burgess A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors Ann Oncol 20 2010 297 304
20. H.G. Augustin, G.Y. Koh, G. Thurston, and K. Alitalo Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system Nat Rev Mol Cell Biol 10 2009 165 177
21. M.J. Currie, S.P. Gunningham, and K. Turner Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia J Pathol 198 2002 502 510
22. A. Coxon, J. Bready, and H. Min Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin- 1/2-neutralizing peptibody Mol Cancer Ther 9 2010 2641 2651
23. J.L. Brown, Z.A. Cao, and M. Pinzon-Ortiz A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models Mol Cancer Ther 9 2010 145 156
24. H. Hashizume, B.L. Falcón, and T. Kuroda Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth Cancer Res 70 2010 2213 2223
25. Y.J. Koh, H.Z. Kim, and S.I. Hwang Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage Cancer Cell 18 2010 171 184
26. B. Rini, C. Szczylik, and N.M. Tannir AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study Cancer 118 24 2012 6152 6161
27. M. Atkins, A. Ravaud, and G. Gravis Safety and efficacy of AMG 386 in combination with sunitinib in patients with metastatic renal cell carcinoma (mRCC) in an open-label multicenter phase II study J Clin Oncol (Meeting abstracts) 30 2012 4606
28. P.H. Patel, P.L. Senico, R.E. Curiel, and R.J. Motzer Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma Clin Genitourin Cancer 7 2009 24 27
29. A.M. Molina, D.R. Feldman, and M.H. Voss Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma Cancer 118 2012 1868 1876
30. M.A. Davies, P.S. Fox, and N.E. Papadopoulos Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma Clin Cancer Res 18 2012 1120 1128
31. E.Q. Lee, J. Kuhn, and K.R. Lamborn Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02 Neurooncol 14 2012 1511 1518
32. T.J. Semrad, C. Eddings, M.P. Dutia, S. Christensen, D. Lau, and P. Lara Phase I study of temsirolimus (Tem) and pazopanib (Paz) in solid tumors with emphasis on renal cell carcinoma (RCC) J Clin Oncol (Meeting Abstracts) 29 2011 e15113
33. F.F. Kabbinavar, S. Srinivas, and R.J. Hauke A phase I trial of combined tivozanib (AV-951) and temsirolimus therapy in patients (pts) with renal cell carcinoma (RCC) J Clin Oncol (Meeting Abstracts) 29 2011 330
34. B.M. Wolpin, K. Ng, and A.X. Zhu Multicenter phase Ib/II study of everolimus (RAD001) and tivozanib (AV-951) in patients with refractory, metastatic colorectal cancer [abstract] J Clin Oncol (Meeting Abstracts) 30 2012 560
35. S. Négrier, G. Gravis, and D. Pérol Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial Lancet Oncol 12 2011 673 680
36. B. Rini, J. Bellmunt, J. Clancy, K. Wang, A. Niethammer, and B. Escudier Randomized Phase IIIb trial of temsirolimus and bevacizumab versus interferon and bevacizumab in metastatic renal cell carcinoma: results from INTORACT Ann Oncol (Meeting Abstracts) 2012 23 LBA21
37. J.D. Hainsworth, D.R. Spigel, H.A. Burris, D. Waterhouse, B.L. Clark, and R. Whorf Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma J Clin Oncol 28 2010 2131 2136
38. A. Ravaud, C. Barrios, and O. Anak Randomized phase II study of first-line everolimus (EVE) + bevacizumab (BEV) versus interferon alfa-2a (IFN) + BEV in patients (pts) with metastatic renal cell carcinoma (mRCC): RECORD-2 Ann Oncol (Meeting Abstracts) 23 2012 7830
39. R.M. Bukowski, F.F. Kabbinavar, and R.A. Figlin Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer J Clin Oncol 25 2007 4536 4541
40. R.J. Motzer, G.R. Hudes, and M.S. Ginsberg Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma Am J Clin Oncol 33 2010 614 618
41. X. Wang, N. Solban, and M.K. Bhasin ALK1-Fc inhibits tumor growth in a VEGF pathway resistance model of renal cell carcinoma Cancer Res (Meeting Abstracts) 72 2012 LB-313
42. T.E. Hutson, L.H. Dang, and R.C. Lauer Phase I/II study of a BNC105P/everolimus regimen for progressive metastatic renal cell carcinoma (mRCC) following prior tyrosine kinase inhibitors (Hoosier Oncology Group) J Clin Oncol (ASCO GU Meeting Abstracts) 30 2012 373
43. R.S. Kerbel, and B.A. Kamen The anti-angiogenic basis of metronomic chemotherapy Nat Rev Cancer 4 2004 423 436
44. G. Klement, S. Baruchel, and J. Rak Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity J Clin Invest 105 2000 15 24
45. T. Browder, C.E. Butterfield, and B.M. Kraling Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer Cancer Res 60 2000 1878 1886
46. J. Bellmunt, J.M. Trigo, and E. Calvo Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06) Lancet Oncol 11 2010 350 357
47. G.G. Chiang, and R.T. Abraham Targeting the mTOR signaling network in cancer Trends Mol Med 13 2007 433 442
48. A.Y. Choo, and J. Blenis Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy Cell Cycle 8 2009 567 572
49. S.Y. Sun, L.M. Rosenberg, and X. Wang Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition Cancer Res 65 2005 7052 7058
50. K. Kondo, W.Y. Kim, M. Lechpammer, and W.G. Kaelin Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth PLoS Biol 1 2003 439 444
51. A. Toschi, E. Lee, N. Gadir, M. Ohh, and D.A. Foster Differential dependence of hypoxia-inducible factors 1 α and 2 α on mTORC1 and mMTORC2 J Biol Chem 283 2008 34495 34499
52. D.C. Cho, M.B. Cohen, and D.J. Panka The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma Clin Cancer Res 16 2010 3628 3638
53. S. Yang, X. Xiao, X. Meng, and K.K. Leslie A mechanism for synergy with combined mTOR and PI3 kinase inhibitors PLoS ONE 6 2011 e26343
54. S.L. Topalian, F.S. Hodi, and J.R. Brahmer Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454